High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

BACKGROUND: Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% respectively. Toxicity limited use to specialized centers with standardized pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Davar, Diwakar, Ding, Fei, Saul, Melissa, Sander, Cindy, Tarhini, Ahmad A., Kirkwood, John M., Tawbi, Hussein A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604296/
https://www.ncbi.nlm.nih.gov/pubmed/28923120
http://dx.doi.org/10.1186/s40425-017-0279-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604296/
https://www.ncbi.nlm.nih.gov/pubmed/28923120
http://dx.doi.org/10.1186/s40425-017-0279-5

Ejemplares similares